ARNI — Arno Therapeutics Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$2.11m
Annual income statement for Arno Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2011 December 31st | 2012 December 31st | 2013 December 31st | 2014 December 31st | 2015 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 7.65 | 10.8 | 16.9 | 21.5 | 13.4 |
| Operating Profit | -7.65 | -10.8 | -16.9 | -21.5 | -13.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.91 | -14.4 | -39.7 | 7.77 | -11.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.91 | -14.4 | -39.7 | 7.77 | -11.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.91 | -14.4 | -39.7 | 7.77 | -11.5 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -7.99 | -14.4 | -39.7 | 7.77 | -11.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.85 | -3.17 | -5.28 | 0.313 | -0.564 |
| Dividends per Share |